People with inflammatory bowel disease (IBD) face a heightened risk of colorectal cancer, yet early detection remains a challenge. Researchers at The Institute of Cancer Research in London have developed a new genetic test that can predict bowel cancer risk in IBD patients with over 90% accuracy, potentially eliminating unnecessary surgeries and reducing patient anxiety.
By analyzing DNA changes in pre-cancerous cells, this test offers a more precise approach than traditional colonoscopy-based surveillance, which can miss early warning signs. Experts praise the innovation as a game-changer in IBD care, with potential future adaptations into blood or stool-based tests for even less invasive screening.
Keep Reading
Add A Comment